Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADJUNCT: Zimberelimab, Domvanalimab and Sacituzumab Govitecan in Advanced TNBC
NCT07134556Phase 2Withdrawn
- Sponsor
- MEDSIR
- Start
- Apr 2026
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of zimberelimab, domvanalimab, sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by MEDSIR. Planned start Apr 2026; status: withdrawn.
02
Drugs
zimberelimabdomvanalimabsacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07134556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134556.